You can buy or sell NanoViricides and other stocks, options, ETFs, and crypto commission-free!
NanoViricides Inc., also called NanoViricides, is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. Read More The company was founded by Anil R. Diwan on July 25, 2000 and is headquartered in Shelton, CT.
52 Week High
52 Week Low
PR NewswireMar 12
NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND
SHELTON, Conn., March 12, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that its first drug candidate has successfully completed another important step in its Safety/Toxicology studies moving towards human clinical trials. The broad-spectrum anti-herpes clinical candidate in the HerpeCide™ program, namely NV-HHV-101, was tested in this study, formulated as a subcutaneous in...
Stock Price, News, & Analysis for NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candid...
Seeking AlphaMar 5
NanoViricides reports positive early-stage data on broad-spectrum drug candidate; shares up 45% premarket
NanoViricides' (NYSEMKT:NNVC) has successfully completed the first safety/toxicology studies evaluating broad-spectrum drug candidate NV-HHV-101, a topical cream formulation, in mini-pigs.
Expected May 21, After Hours